Gyre Therapeutics Inc. - Asset Resilience Ratio

Latest as of March 2026: 7.60%

Gyre Therapeutics Inc. (GYRE) has an Asset Resilience Ratio of 7.60% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See GYRE net working capital ratio to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

$12.31 Million

Cash + Short-term Investments

Total Assets

$162.01 Million

All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2006–2025)

This chart shows how Gyre Therapeutics Inc.'s Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Gyre Therapeutics Inc. asset portfolio.

Liquid Assets Composition Over Time

This chart breaks down Gyre Therapeutics Inc.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore GYRE long-term investments to assets to see how much of total assets are deployed in long-term investments.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	$0.00	0%
Short-term Investments	$12.31 Million	7.6%
Total Liquid Assets	$12.31 Million	7.60%

Asset Resilience Insights

Limited Liquidity: Gyre Therapeutics Inc. maintains only 7.60% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

Gyre Therapeutics Inc. Industry Peers by Asset Resilience Ratio

Compare Gyre Therapeutics Inc.'s asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
ALK-Abelló A/S CO:ALK-B	Biotechnology	0.98%
Mirum Pharmaceuticals Inc NASDAQ:MIRM	Biotechnology	6.89%
Xiamen Amoytop Biotech Co Ltd SHG:688278	Biotechnology	4.69%
BB Biotech AG SW:BION	Biotechnology	92.97%
Soleno Therapeutics Inc NASDAQ:SLNO	Biotechnology	20.15%
Nanobiotix NASDAQ:NBTX	Biotechnology	4.71%
Wuhan Keqian Biology Co Ltd SHG:688526	Biotechnology	19.42%
Beijing Konruns Pharmaceutical Co Ltd SHG:603590	Biotechnology	10.55%

Annual Asset Resilience Ratio for Gyre Therapeutics Inc. (2006–2025)

The table below shows the annual Asset Resilience Ratio data for Gyre Therapeutics Inc..

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	9.24%	$15.36 Million	$166.13 Million	-2.61pp
2024-12-31	11.85%	$14.86 Million	$125.41 Million	--
2023-12-31	0.00%	$0.00	$116.54 Million	--
2022-12-31	12.50%	$10.60 Million	$84.75 Million	+8.00pp
2021-12-31	4.50%	$2.50 Million	$55.66 Million	-47.16pp
2020-12-31	51.66%	$48.99 Million	$94.85 Million	-10.74pp
2019-12-31	62.40%	$61.50 Million	$98.55 Million	-8.78pp
2018-12-31	71.18%	$88.91 Million	$124.92 Million	+25.70pp
2017-12-31	45.48%	$17.97 Million	$39.51 Million	+27.63pp
2016-12-31	17.85%	$6.80 Million	$38.09 Million	+12.96pp
2015-12-31	4.89%	$3.40 Million	$69.52 Million	-40.60pp
2014-12-31	45.50%	$50.95 Million	$112.00 Million	+19.55pp
2013-12-31	25.94%	$37.84 Million	$145.87 Million	+3.41pp
2012-12-31	22.53%	$42.72 Million	$189.58 Million	-11.45pp
2011-12-31	33.98%	$87.72 Million	$258.13 Million	+15.65pp
2010-12-31	18.33%	$48.17 Million	$262.79 Million	+9.83pp
2009-12-31	8.50%	$27.16 Million	$319.38 Million	-29.20pp
2008-12-31	37.71%	$37.16 Million	$98.55 Million	+3.72pp
2007-12-31	33.99%	$33.64 Million	$98.96 Million	+18.69pp
2006-12-31	15.29%	$12.45 Million	$81.37 Million	--

pp = percentage points

About Gyre Therapeutics Inc.

NASDAQ:GYRE USA Biotechnology

Market Cap

$650.09 Million

Market Cap Rank

#11295 Global

#2929 in USA

Share Price

$6.70

Change (1 day)

+0.15%

52-Week Range

$5.56 - $8.87

All Time High

$612.86